G-CSF for imatinib-induced neutropenia

被引：15
|
作者：
Heim, D [1 ]
Ebnöther, M [1 ]
Meyer-Monard, S [1 ]
Tsakiris, D [1 ]
Linn, M [1 ]
Tichelli, A [1 ]
Gratwohl, A [1 ]
机构：
[1] Novartis Pharma Schweiz AG, Bern, Switzerland
来源：
LEUKEMIA | 2003年 / 17卷 / 04期
关键词：
D O I：
10.1038/sj.leu.2402869
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：805 / 807
页数：3
相关论文
共 50 条
  • [1] G-CSF for Imatinib-induced neutropenia
    D Heim
    M Ebnöther
    S Meyer-Monard
    D Tsakiris
    M Linn
    A Tichelli
    A Gratwohl
    Leukemia, 2003, 17 : 805 - 807
  • [2] G-CSF FOR FEVER AND NEUTROPENIA INDUCED BY CHEMOTHERAPY
    AUCHTER, RM
    NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (04): : 269 - 270
  • [3] G-CSF IN RADIOTHERAPY-INDUCED NEUTROPENIA
    BURRAI, I
    IACOANGELI, M
    PETTI, R
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1993, 12 (04) : 265 - 268
  • [4] G-CSF FOR FEVER AND NEUTROPENIA INDUCED BY CHEMOTHERAPY - REPLY
    CRAWFORD, J
    GLASPY, JA
    NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (04): : 270 - 270
  • [5] G-CSF and GM-CSF in Neutropenia
    Mehta, Hrishikesh M.
    Malandra, Michael
    Corey, Seth J.
    JOURNAL OF IMMUNOLOGY, 2015, 195 (04): : 1341 - 1349
  • [6] G-CSF plasma levels in clozapine-induced neutropenia
    Jauss, M
    Pantel, J
    Werle, E
    Schröder, J
    BIOLOGICAL PSYCHIATRY, 2000, 48 (11) : 1113 - 1115
  • [7] Neutropenia and G-CSF in lymphoproliferative diseases
    Ria, Roberto
    Reale, Antonia
    Moschetta, Michele
    Dammacco, Franco
    Vacca, Angelo
    HEMATOLOGY, 2013, 18 (03) : 131 - 137
  • [8] Correction of mesalazine-induced neutropenia with high dose G-CSF
    Bhidayasiri, R
    Katz, JA
    Sokos, DR
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2000, 95 (11): : 3321 - 3322
  • [9] SEVERE CONGENITAL NEUTROPENIA UNRESPONSIVE TO G-CSF
    RYAN, M
    WILL, AM
    TESTA, N
    HAYWORTH, C
    DARBYSHIRE, PJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (01) : 43 - 45
  • [10] New G-CSF agonists for neutropenia therapy
    Hoggatt, Jonathan
    Pelus, Louis M.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (01) : 21 - 35
12345